With the likelihood increasing that the United Kingdom will leave the European Union without a trade agreement in early 2019, the UK Health Secretary, Matt Hancock, has issued new advice to the pharmaceutical industry in which he warned that there could be long border delays that seriously impact the flow of pharmaceuticals in Europe.
With the likelihood increasing that the United Kingdom will leave the European Union without a trade agreement in early 2019, the UK Health Secretary, Matt Hancock, has issued new advice to the pharmaceutical industry in which he warned that there could be long border delays that seriously impact the flow of pharmaceuticals in Europe.
In the letter, Hancock explained that the Medicines Supply Contingency Planning Programme (MSCPP), established expressly to address the supply of drugs in the case of a so-called “no-deal Brexit,” has been working closely with industry to support efforts to stockpile additional 6-week supplies of medications on top of companies’ usual stocks. In addition, the MSCPP has been working with companies that supply shorter shelf-life products to arrange to fly these medicines in via air-freight arrangements and with wholesalers of pharmaceutical warehouse space to secure the capacity needed to house stockpiled medicines.
Now, says Hancock, to address potential trade delays that could disrupt the flow of crucial medicines across borders for as long as 6 months, the UK government is devising new procedures that will prioritize the flow of medicines and vaccines at its border. However, he emphasized that the United Kingdom cannot control whether the European Union will do the same.
“This is very much a worst-case scenario,” wrote Hancock, adding that “we would, or course, be pressing [EU] member states hard to introduce pragmatic arrangements to ensure the continued full flow of goods.” As far as logistics for the new border procedures are concerned, Hancock said that the MSCPP would follow up with industry “very shortly.”
Industry was quick to respond to Hancock’s letter with calls for greater clarity. Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI), said in an organizational statement, “The update on potential border delays for 6 months in a no-deal scenario is stark. Stockpiling more medicines is not the solution to this problem. We welcome the Secretary of State’s intention to prioritise the flow of medicines and vaccines. But with just 16 weeks until the [United Kingdom] leaves the [European Union], we need the detail.” Thompson added that “The Government should to take immediate action to open up alternative supply routes…and tell companies so that they can make plans.”
Warwick Smith, director general of the British Generic Manufacturers Association, echoed calls for greater detail clarity from the government officials. “Our members have cooperated with the Government’s request for holding additional stocks and providing data to allow them to assess the risk to the supply of medicines, and to work with us on putting in place mitigating measures…It is vitally important that the Government shares with us and others all their current information so that we can plan accordingly.”
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
BioRationality: EMA Announces Readiness to Waive Comparative Efficacy Studies of Biosimilars
March 4th 2024Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive regulatory approval.